Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Biotechnology

Healthcare
$9.28 +2.44%

+$0.31 today

Market cap
$552.20M
Beta
0.89
P/E (TTM)
6.1
EPS (TTM)
$2.13
52W Low $7.16High $14.27

Volume 0.62M

Average 1.43M

ZVRA Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Zevra Therapeutics, Inc.NASDAQ: ZVRA

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures dips below year-ago levels

Q1 FY2026 capital expenditures of $35K (cash outflow) fell 64.6% year over year, behind the +678.8% change in trailing-twelve-month capital expenditures. Over 3 fiscal years it compounded at +107.8% a year.

Context

  • Capital expenditures amounted to 0.8% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Capital expenditures increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -64.6% toward the trailing-twelve-month pace of +678.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$35K-212.9% QoQ
Last fiscal yearDec 2025
-$835K— YoY
LTMMar 2026
-$771K+678.8% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-64.6%——
1 year———
3-year CAGR+107.8%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(835K) USD
Year-over-year change
—

Capital Expenditures vs competitors

How ZVRA compares with its peers on the latest reported figures

  • ZVRA's LTM Mar 2026 capital expenditures of $771K is the 7th largest of the 11 companies compared; the peer median is $1.05M.
  • Its year-over-year change of +678.8% is the 2nd highest of 10, against a peer median of -20.1%.
  • Capital expenditures amounts to 0.6% of revenue for ZVRA, versus a peer median of 0.8%.
ZVRA Competitors Peer median
Capital Expenditures for ZVRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JAZZJazz Pharmaceuticals plcLTM Sep 2026$119.73M +116.5%-25.1%2.5%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$26.1M -40.3%+27.3%0.7%
ALKSAlkermes plcLTM Sep 2026$15.62M -68.9%+1.9%0.9%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$1.12M -5.9%+48.1%0.1%
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$1.09M +805.0%-49.9%—
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$1.01M -20.1%-34.9%—
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$771K +678.8%+107.8%0.6%
ANROAlto Neuroscience, Inc.LTM Mar 2026$556K -70.3%-68.0%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$497K -35.3%-14.1%—
GHRSGH Research PLCLTM Mar 2026$181.36K +342.3%+21.8%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$16K ———
Peer median (excluding ZVRA) $1.05M-20.1%-14.1%0.8%

Competitors are the stored peer set for ZVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(8.56M)(41.54M)(46.05M)(105.51M)83.23M
Depreciation & Amortization257K944K1.01M6.39M4.05M
Deferred Income Tax16.2M0015.37M3.45M
Stock-Based Compensation2.44M4.29M5.95M14.91M12.63M
Change in Working Capital(357K)(406K)5.88M(6.64M)(26.51M)
Accounts Receivables1.05M(6.77M)(9.08M)6.87M(11.98M)
Inventory0147K206K(8.87M)(1.31M)
Accounts Payables(1.11M)3.13M11.13M(3.6M)(15.59M)
Other Working Capital(295K)3.09M3.63M(1.04M)2.36M
Other Non-Cash Items460K17.99M(329K)5.82M(78.45M)
Operating Cash Flow10.44M(18.72M)(33.54M)(69.67M)(1.6M)
Capital Expenditures(102K)(93K)(296K)0(835K)
Acquisitions (Net)0(14.09M)(30.4M)00
Purchases of Investments(15.42M)(22.54M)(45.81M)(41.16M)(309.99M)
Sales of Investments036.63M59.12M25M328.5M
Other Investing Activities0(36.63M)0(6M)448K
Investing Cash Flow(15.52M)(36.72M)(17.39M)(22.16M)18.13M
Debt Repayment(38.1M)12.78M25.59M16.29M0
Common Stock Issued49.29M324K6.32M64.52M12.44M
Common Stock Repurchased(2.81M)(4.72M)(3.45M)00
Dividends Paid00000
Other Financing Activities104.74M291K6.32M1.3M(372K)
Financing Cash Flow113.11M8.35M28.46M82.11M12.06M
Effect of Forex Changes0204K44K454K28K
Net Change in Cash108.02M(46.88M)(22.42M)(9.26M)28.62M
Free Cash Flow10.34M(18.81M)(33.83M)(69.67M)(2.43M)

Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Intrinsic Alpha fair value

Locked

Current Price

$9.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.